Integrated sequencing utilized in a timely and impactful manner in AML|MDS

Charles Mullighan, MBBS, MD, St. Jude Children's Hospital, Memphis, TN, discusses the late-breaking work from his group in collaboration with the Munich Leukemia Laboratory. He explains how the integrated transcriptomic and genomic sequencing of driver mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has identified prognostic constellations, and highlights the importance of the work - showing that this approach can be utlilized in a timely and impactful manner. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Speaker: Charles Mullighan,Event: ASH 2019,Format: Interview,late-breaking,Subject: Leukemia,Subject: Acute Myeloid Leukemia,Subject: Myelodysplastic Syndromes,Field: Disease Biology,Field: Diagnosis,transcriptome,genomic sequencing,gene expression,mutations,subtypes,classification,sequencing,WGS,RNA-seq,prognostic marker,highlights,